MedTrace Logo

Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin

NCT01128712 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2017-09-14

No results posted yet for this study

Summary

To prospectively demonstrate the superior anxiolytic effect of high dose pregabalin (PGB) therapy (450 mg/day) compared to low dose PGB therapy (150 mg/day) in subjects with medically refractory partial epilepsy not fully controlled despite treatment with 1-2 concomitant antiepileptic drugs (AEDs).

Conditions

  • Epilepsy, Complex Partial

Interventions

DRUG

Pregabalin

150 mg /day

DRUG

Pregabalin

450 mg/day

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Northeast Regional Epilepsy Group

    lead OTHER

Principal Investigators

  • Evan Fertig, MD · Northeast Regional Epilepsy Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01128712 on ClinicalTrials.gov